SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-043039
Filing Date
2021-08-16
Accepted
2021-08-16 16:25:55
Documents
37
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0621_rasnatherap.htm   iXBRL 10-Q 372016
2 CERTIFICATION f10q0621ex31-1_rasnatherap.htm EX-31.1 14141
3 CERTIFICATION f10q0621ex32-1_rasnatherap.htm EX-32.1 5892
  Complete submission text file 0001213900-21-043039.txt   2041526

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20210630.xsd EX-101.SCH 19094
5 XBRL CALCULATION FILE rasp-20210630_cal.xml EX-101.CAL 22798
6 XBRL DEFINITION FILE rasp-20210630_def.xml EX-101.DEF 97980
7 XBRL LABEL FILE rasp-20210630_lab.xml EX-101.LAB 195410
8 XBRL PRESENTATION FILE rasp-20210630_pre.xml EX-101.PRE 104311
9 EXTRACTED XBRL INSTANCE DOCUMENT f10q0621_rasnatherap_htm.xml XML 179721
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 211178723
SIC: 2834 Pharmaceutical Preparations